Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma - PubMed
9 hours ago
- #immunotherapy
- #nasopharyngeal carcinoma
- #systemic therapy
- Study compares immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) after first-line therapy failure.
- 794 RM-NPC patients analyzed from February 2014 to August 2023 across five treatment groups.
- Treatment groups: anti-PD-1 monotherapy (P), anti-PD-1 plus antiangiogenic (AP), anti-PD-1 plus single-agent chemo (C1P), anti-PD-1 plus two-agent chemo (C2P), and anti-PD-1 plus antiangiogenic plus chemo (CAP).
- Median PFS: P (3.6 months), AP (8.5 months), C1P (7.6 months), C2P (12.7 months), CAP (16.3 months).
- Median OS: P (35.8 months), AP (46.6 months), C1P (50.9 months), C2P (50.6 months), CAP (47.2 months).
- Combination therapies (CAP, C2P, C1P, AP) showed significantly better PFS than monotherapy (P).
- Grade 3-4 TRAEs higher in C1P (34.3%) vs. AP (16.9%) and C2P (54.0%) vs. CAP (42.7%).
- Anti-PD-1 combination therapy improves PFS in RM-NPC patients post first-line therapy failure.